A Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01306630
Recruitment Status : Completed
First Posted : March 2, 2011
Last Update Posted : January 27, 2014
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.

Brief Summary:
This is an open-label, multi-center, dose-finding study of tivozanib administered in combination with capecitabine. During the dose-escalation portion, sequential cohorts of subjects with advanced solid tumors will be enrolled in order to establish the maximum tolerated dose (MTD). If the MTD is not reached, the recommended Phase 2 dose (RP2D) will be determined. In the expansion cohort, subjects with locally advanced or metastatic breast or colon cancer will be enrolled at MTD (or RP2D) to further evaluate safety and activity of this combination in these tumor types.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Locally Advanced or Metastatic Breast or Colorectal Cancer Drug: tivozanib (AV-951) and capecitabine (Xeloda®) Phase 1

Detailed Description:
This is a Phase Ib, open-label, multi-center, dose-escalation study of orally administered tivozanib in combination with capecitabine to approximately 24 subjects with advanced solid tumors and, in the expanded MTD cohort, subjects with locally advanced or metastatic breast or colorectal cancer. This study is designed to evaluate the safety, tolerability, dose-limiting toxicities, maximum tolerated dose, pharmacokinetic, and antineoplastic activity. The number of cohorts evaluated and the maximum doses to be administered will depend upon the observed tolerability. Dose level "0", tivozanib HCl 1.5 mg and capecitabine 1000 mg/m² BID, is the starting dose level. Once assigned to a cohort, each subject will continue to be treated at the same dose level and schedule throughout the course of the study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda®) in Subjects With Advanced Solid Tumors
Study Start Date : November 2010
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
tivozanib + capecitabine Drug: tivozanib (AV-951) and capecitabine (Xeloda®)
Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measures :
  1. To determine the safety, tolerability, and maximum tolerated dose of tivozanib when administered in combination with capecitabine (Xeloda®) to subjects with advanced solid tumors [ Time Frame: daily for 6 weeks ]
    Assessment of any dose-limiting toxcities

Secondary Outcome Measures :
  1. Evaluate the pharmacokinetics of tivozanib, and capecitabine and its metabolites by measuring the serum plasma concentrations of tivozanib and capecitabine in the blood over time. [ Time Frame: Cycle 1 (Days 1, 2, 8, 14, and 15), Cycle 2 (Days 1 and 14), Cycles 3, 5, 7, and 9 (Day 1 only). ]
    PK parameters of tivozanib and capecitabine will be calculated from serum and plasma levels. These will be summarized descriptively and presented by visit and dose cohort. PK parameters will be calculated using non compartmental and/or compartmental models and PK parameters will be summarized and presented. The mean (± STDEM) concentration-time profiles of tivozanib, capecitabine, and their metabolite(s) will be presented for each dose.

  2. To evaluate the antineoplastic activity of tivozanib and capecitabine, when given together, to slow the growth of or shrink tumor as measured by CT/MRI imaging assessment and according to RECIST criteria. [ Time Frame: every 6 weeks ]
    Disease and response assessments will be determined using Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0). Disease assessment is to include disease classification, tumor marker assessments, and diagnostic imaging / measurement of marker lesions. Computerized tomography (CT) will be considered the standard method for evaluating disease status. All subjects should have a CT scan (or MRI) of the head, chest, abdomen, and pelvis at baseline. The location and dimensions of "marker" lesions will be documented.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age 18 years or older, of either sex, and of any race.
  2. Histologically or cytologically confirmed solid tumor malignancy.
  3. Dose escalation cohorts: Advanced solid tumor malignancy (locally advanced or metastatic) that has recurred or progressed following standard therapy or for which no standard therapy currently exists, or for which subject is not a candidate for - standard therapy, or is unwilling to undergo standard therapy.
  4. MTD expansion cohort: Subjects must have locally advanced or metastatic breast or colorectal cancer with or without prior systemic therapy.
  5. ECOG performance ≤ 2 (Appendix B) and life expectancy ≥ 3 months.
  6. Disease that is not amenable to curative surgical intervention, due to either non-resectability of the tumor or medical contraindications.
  7. Subjects enrolled in the MTD expansion cohort must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0.
  8. At least 4 weeks since :

    • Vascular endothelial growth factor (VEGF) or VEGF receptor directed therapy

    • Chemotherapy (6 weeks since prior mitomycin C or nitrosoureas)
    • Immunotherapy (eg, IL-2, IFN, etc.) or biological therapy (eg, monoclonal antibodies)
    • Investigational agents
  9. At least 2 weeks since:

    • Systemic hormonal therapy (with the exception of hormone replacement therapy or low dose steroid therapy as described in Drugs and Treatments to be Excluded)
    • Herbal preparations (including daily multivitamin/mineral supplements containing herbal components)
  10. At least 2 weeks since prior radiotherapy to ≤ 25% of bone marrow, or at least 4 weeks since prior radiotherapy to > 25% of bone marrow.
  11. If female and of child bearing potential, documentation of negative pregnancy test prior to enrollment.
  12. Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for 30 days after the last dose of study drug. All fertile subjects (and their partners) must agree to use a highly effective method of contraception. Effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)
  13. Adequate hematologic function as evidenced by Hg ≥ 9g/dL, WBC ≥ 3000 per mm3, ANC ≥ 1500 per mm3 and platelet count ≥ 100,000 per mm3.
  14. Adequate hepatic function as evidenced by a serum bilirubin level ≤1.5 × ULN (except with known Gilbert's Syndrome) and serum AST/ALT levels ≤2.5 × ULN (or ≤5 × ULN for subjects with known hepatic metastasis).
  15. Adequate renal function as evidenced by a serum creatinine level ≤ 1.5 × ULN (subjects with a serum creatinine level >1.5 x ULN with a calculated creatinine clearance > 50 mL/min according to Cockcroft-Gault equation will be eligible).
  16. Proteinuria ≤3+ by urinalysis or urine dipstick (subjects with proteinuria >3 + may undergo a 24-hour urine protein and will be eligible if protein is <2 g/24hrs)
  17. Adequate coagulation parameters: PTT ≤ 1.5 x ULN and INR ≤ 1.5
  18. Ability to give written informed consent and comply with protocol requirements.

Exclusion Criteria:

  • 1. Primary CNS malignancies or CNS metastases; subjects with previously treated brain metastasis will be allowed if the brain metastasis has been stable without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery). Subjects with symptoms of CNS metastases or history must have a CT or MRI scan including the brain during Screening.

    2. Significant cardiovascular disease, including:

    • Active clinically symptomatic left ventricular failure

    • Uncontrolled hypertension: Systolic blood pressure > 140 mmHg or diastolic blood pressure >90 mmHg on 2 or more antihypertensive medications. Note: Initiation or adjustment of antihypertensive medication(s) is permitted during the screening period, in order to control a subject's BP prior to initiating treatment. Blood pressure must be re-assessed on two occasions that are separated by a minimum of 1 hour. The SBP / DBP values from each blood pressure assessment must be ≤ 140/90 mmHg in order for a subject to be eligible for the study
    • Myocardial infarction, severe or unstable angina within 6 months prior to administration of first dose of study drug
    • History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation)
    • Cardiac arrhythmias requiring anti-arrhythmic medications
    • History of coronary or peripheral artery bypass graft within 6 months

      3. Significant thromboembolic or vascular disorders within 6 months prior to first dose of study drug; this does NOT include catheter-related thrombosis. Significant thromboembolic or vascular disorders include but are not limited to:

    • Deep vein thrombosis
    • Pulmonary embolism
    • Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
    • Symptomatic peripheral vascular disease

      4. Subjects with non-healing wounds, active peptic ulcers, or unhealed bone fractures.

      5. Known dihydropyrimidine dehydrogenase (DPD) deficiency.

      6. Known hypersensitivity to fluoropyrimidine therapy or to 5-fluorouracil.

      7. Known inability to tolerate capecitabine (Xeloda®) due to unacceptable toxicities.

      8. Serious active infection, (including active Hepatitis B or Hepatitis C) or infection requiring parenteral antibiotics.

      9. Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug.

      10. Significant bleeding disorders within 6 months prior to first dose of study drug, including but not limited to:

    • Hematemesis, hematochezia, melena or other gastrointestinal bleeding
    • Hemoptysis or other pulmonary bleeding
    • Hematuria or other genitourinary bleeding

      11. Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for >2 years.

      12. Pregnant or lactating females.

      13. Known concomitant genetic or acquired immune suppression disease such as HIV.

      14. Centrally located lung cancer, or evidence of solid tumor invading major blood vessels on imaging.

      15. Malabsorption, uncontrolled vomiting or diarrhea, or any disease significantly affecting gastrointestinal function that could interfere with absorption of study drugs, or inability to swallow oral drugs.

Drugs and Treatments to be Excluded

  1. Chemotherapy, biological therapy (including cytokines, signal transduction inhibitors, monoclonal antibodies), immunotherapy or any other therapy for solid tumors.
  2. Systemic hormonal therapy, with the exception of:

    • Hormonal therapy for appetite stimulation or contraception
    • Nasal, ophthalmic, inhaled and topical steroid preparations
    • Androgen suppression therapy for non-metastatic prostate carcinoma
    • Hormone replacement therapy for conditions such as adrenal insufficiency, hypothyroidism, diabetes, etc.
    • Low-dose maintenance steroid therapy (equivalent of prednisone ≤ 10 mg/day) for other conditions
  3. Treatment with radiotherapy (limited radiotherapy involving ≤ 25% of bone marrow may be allowed for palliative purposes after consultation with the medical monitor. Treatment with study drugs (tivozanib and capecitabine) must be stopped during radiotherapy).
  4. Herbal preparations/supplements (including daily multivitamin/mineral supplement containing herbal components).
  5. Treatment with full dose oral anticoagulants such as warfarin, acenocoumarol, fenprocoumon, or similar agents. If previously receiving these types of agents, a minimum washout of 1 week and documented INR of ≤ 1.5 will be required prior to start of therapy. Full dose anticoagulation with low molecular weight heparin or unfractionated heparin administered subcutaneously is allowed. Low dose oral anticoagulation (eg, 1-2 mg/day warfarin) is allowed provided INR remains ≤ 1.5 during the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01306630

United States, Arizona
Scottsdale, Arizona, United States, 85258
United States, Florida
Fort Myers, Florida, United States, 33908
United States, Tennessee
Nashville, Tennessee, United States, 37203
Sponsors and Collaborators
AVEO Pharmaceuticals, Inc.
Study Director: Shefali Agarwal, M.D. AVEO Pharmaceuticals, Inc.

Responsible Party: AVEO Pharmaceuticals, Inc. Identifier: NCT01306630     History of Changes
Other Study ID Numbers: AV-951-10-114
First Posted: March 2, 2011    Key Record Dates
Last Update Posted: January 27, 2014
Last Verified: January 2014

Keywords provided by AVEO Pharmaceuticals, Inc.:
capecitabine (Xeloda®)

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents